Prognostic Value of Serum Epstein–Barr Virus Antibodies and Their Correlation with TNM Classification in Patients with Locoregionally Advanced Nasopharyngeal Carcinoma
2
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Purpose This study assessed the correlation between Epstein-Barr virus (EBV) biomarkers and the eighth American Joint Committee on Cancer staging system and the prognostic values of IgG antibodies against replication and transcription activator (Rta-IgG), IgA antibodies against Epstein-Barr nuclear antigen 1, and BamH1 Z transactivator (Zta-IgA) in locoregionally advanced nasopharyngeal carcinoma (NPC) patients. Materials and Methods Serum EBV antibody levels were measured by enzyme-linked immunosorbent assay in 435 newly diagnosed stage III-IVA NPC patients administered intensity-modulated radiation therapy±chemotherapy. The primary endpoint was progression-free survival (PFS). Results Rta-IgG and Zta-IgA levels were positively correlated with the N category and clinical stage. Patients with high Rta-IgG levels (> 29.07 U/mL) showed a significantly inferior prognosis as indicated by PFS (77% vs. 89.8%, p=0.004), distant metastasis–free survival (DMFS) (88.3% vs. 95.8%, p=0.021), and local recurrence-free survival (LRFS) (91.2% vs. 98.3%, p=0.009). High Rta-IgG levels were also significantly associated with inferior PFS and LRFS in multivariable analyses. In the low-level EBV DNA group (≤ 1,500 copies/mL), patients with high Rta-IgG levels had significantly inferior PFS and DMFS (both p < 0.05). However, in the high-level EBV DNA group, Rta-IgG levels were not significantly associated with PFS, DMFS, and LRFS. In the advanced T category (T3-4) subgroup, high Rta-IgG levels were also significantly associated with inferior PFS, DMFS, and LRFS (both p < 0.05). Conclusion Rta-IgG and Zta-IgA levels were strongly correlated with the TNM classification. Rta-IgG level was a negative prognostic factor in locoregionally advanced NPC patients, especially those with advanced T category or low EBV DNA level.
Abstract
Purpose This study assessed the correlation between Epstein-Barr virus (EBV) biomarkers and the eighth American Joint Committee on Cancer staging system and the prognostic values of IgG antibodies against replication and transcription activator (Rta-IgG), IgA antibodies against Epstein-Barr nuclear antigen 1, and BamH1 Z transactivator (Zta-IgA) in locoregionally advanced nasopharyngeal carcinoma (NPC) patients. Materials and Methods Serum EBV antibody levels were measured by enzyme-linked immunosorbent assay in 435 newly diagnosed stage III-IVA NPC patients administered intensity-modulated radiation therapy±chemotherapy. The primary endpoint was progression-free survival (PFS). Results Rta-IgG and Zta-IgA levels were positively correlated with the N category and clinical stage. Patients with high Rta-IgG levels (> 29.07 U/mL) showed a significantly inferior prognosis as indicated by PFS (77% vs. 89.8%, p=0.004), distant metastasis–free survival (DMFS) (88.3% vs. 95.8%, p=0.021), and local recurrence-free survival (LRFS) (91.2% vs. 98.3%, p=0.009). High Rta-IgG levels were also significantly associated with inferior PFS and LRFS in multivariable analyses. In the low-level EBV DNA group (≤ 1,500 copies/mL), patients with high Rta-IgG levels had significantly inferior PFS and DMFS (both p < 0.05). However, in the high-level EBV DNA group, Rta-IgG levels were not significantly associated with PFS, DMFS, and LRFS. In the advanced T category (T3-4) subgroup, high Rta-IgG levels were also significantly associated with inferior PFS, DMFS, and LRFS (both p < 0.05). Conclusion Rta-IgG and Zta-IgA levels were strongly correlated with the TNM classification. Rta-IgG level was a negative prognostic factor in locoregionally advanced NPC patients, especially those with advanced T category or low EBV DNA level.
참고문헌 (30)
- Yu WM, "Incidence of nasopharyngeal carcinoma in Chinese immigrants, compared with Chinese in China and South East Asia : review", J Laryngol Otol, 123, pp.1067~1074 (2009)
- Chang ET, "The enigmatic epidemiology of nasopharyngeal carcinoma", Cancer Epidemiol Biomarkers Prev, 15, pp.1765~1777 (2006)
- Yi JL, "Nasopharyngeal carcinoma treated by radical radiotherapy alone : Ten-year experience of a single institution", Int J Radiat Oncol Biol Phys, 65, pp.161~168 (2006)
- Leung SF, "Pretherapy quantitative measurement of circulating EpsteinBarr virus DNA is predictive of posttherapy distant failure in patients with early-stage nasopharyngeal carcinoma of undifferentiated type", Cancer, 98, pp.288~291 (2003)
- Leung SF, "Plasma Epstein-Barr viral deoxyribonucleic acid quantitation complements tumor-node-metastasis staging prognostication in nasopharyngeal carcinoma", J Clin Oncol, 24, pp.5414~5418 (2006)
- Gu AD, "The criteria to confirm the role of Epstein-Barr virus in nasopharyngeal carcinoma initiation", Int J Mol Sci, 13, pp.13737~13747 (2012)
- Leung SF, "Plasma Epstein-Barr viral DNA load at midpoint of radiotherapy course predicts outcome in advanced-stage nasopharyngeal carcinoma", Ann Oncol, 25, pp.1204~1208 (2014)
- Sun P, "Serologic biomarkers of Epstein-Barr virus correlate with TNM classification according to the seventh edition of the UICC", AJCC staging system for nasopharyngeal carcinoma, 2014, pp.271, 2545~2554
- Shao JY, "Comparison of plasma Epstein-Barr virus(EBV)DNA levels and serum EBV immunoglobulin A", virus capsid antigen antibody titers in patients with nasopharyngeal carcinoma, 2004, pp.100, 1162~1170
- Cai YL, "Relationship between clinical stages of nasopharyngeal carcinoma and Epstein-Barr virus antibodies Rta", IgG, EBNA1, IgA and EA, pp.IgA, Nan Fang Yi Ke Da Xue Xue Bao[DOI]
- Yao JJ, "Prognostic value of serum Epstein-Barr virus antibodies in patients with nasopharyngeal carcinoma and undetectable pretreatment Epstein-Barr virus DNA", Cancer Sci, 108, pp.1640~1647 (2017)
- Lee AW, "Potential improvement of tumor control probability by induction chemotherapy for advanced nasopharyngeal carcinoma", Radiother Oncol, 87, pp.204~210 (2008)
- Lin S, "Sequential chemotherapy and intensity-modulated radiation therapy in the management of locoregionally advanced nasopharyngeal carcinoma : experience of 370 consecutive cases", BMC Cancer, 10, pp.39~ (2010)
- Xu FH, "An epidemiological and molecular study of the relationship between smoking, risk of nasopharyngeal carcinoma, and Epstein-Barr virus activation", J Natl Cancer Inst, 104, pp.1396~1410 (2012)
- Liu Y, "Establishment of VCA and EBNA1 IgA-based combination by enzymelinked immunosorbent assay as preferred screening method for nasopharyngeal carcinoma : a two-stage design with a preliminary performance study and a mass screening in southern China", Int J Cancer, 131, pp.406~416 (2012)
- Zeng Y, "Prospective studies on nasopharyngeal carcinoma in EpsteinBarr virus IgA", VCA antibody-positive persons in Wuzhou City, China, 1985, pp.36, 545~547
- Ji MF, "Sustained elevation of Epstein-Barr virus antibody levels preceding clinical onset of nasopharyngeal carcinoma", Br J Cancer, 96, pp.623~630 (2007)
- Ling W, "Prognostic implication of pretreatment titer of serum immunoglobulin A against Epstein-Barr virus capsid antigen in nasopharyngeal carcinoma patients in Sihui, Guangdong", Ai Zheng, 28, pp.57~59 (2009)
- Sun R, "Prognostic value and differences of the sixth and seventh editions of the UICC", AJCC staging systems in nasopharyngeal carcinoma, 2013, pp.139, 307~314
- Lo YM, "Kinetics of plasma Epstein-Barr virus DNA during radiation therapy for nasopharyngeal carcinoma", Cancer Res, 60, pp.2351~2355 (2000)
- Chen WH, "Prognostic value of plasma Epstein-Barr virus DNA for local and regionally advanced nasopharyngeal carcinoma treated with cisplatin-based concurrent chemoradiotherapy in intensity-modulated radiotherapy era", Medicine (Baltimore), 95, pp.e2642~ (2016)
- Du YY, "Combining pretreatment plasma Epstein-Barr virus DNA level and cervical node necrosis improves prognostic stratification in patients with nasopharyngeal carcinoma : a cohort study", Cancer Med, 8, pp.6841~6852 (2019)
- Hau PM, "Role of ATM in the formation of the replication compartment during lytic replication of Epstein-Barr virus in nasopharyngeal epithelial cells", J Virol, 89, pp.652~668 (2015)
- Zebboudj A, "Sodium arsenite induces apoptosis and Epstein-Barr virus reactivation in lymphoblastoid cells", Biochimie, 107(Pt B), pp.247~256 (2014)
- Xiao L, "Biomarker discovery of nasopharyngeal carcinoma by proteomics", Expert Rev Proteomics, 11, pp.215~225 (2014)
- Sun R, "Correlation analysis of nasopharyngeal carcinoma TNM staging with serum EA IgA and VCA IgA in EBV and VEGF-C and-D", Med Sci Monit, 21, pp.2105~2109 (2015)
- He YQ, "The relationship between environmental factors and the profile of Epstein-Barr virus antibodies in the lytic and latent infection periods in healthy populations from endemic and nonendemic nasopharyngeal carcinoma areas in China", EBioMedicine, 30, pp.184~191 (2018)
- Xu XF, "Rta-IgG as a biomarker for diagnosis and post treatment prognostic of nasopharyngeal carcinoma", Cancer Biomark, 16, pp.467~476 (2016)
- Cai YL, "Diagnostic significance of combined detection of Epstein-Barr virus antibodies, VCA", IgA, EA, IgG and EBNA1, pp.IgA for nasopharyngeal carcinoma, Asian Pac J Cancer Prev[DOI]
- Lin JC, "Quantification of plasma Epstein-Barr virus DNA in patients with advanced nasopharyngeal carcinoma", N Engl J Med, 350, pp.2461~2470 (2004)